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Abstract: Multiple sclerosis (MS) incidence and serum 25-hydroxyvitamin D (25OHD) levels vary by
race/ethnicity. We examined the consistency of beneficial effects of 25OHD and/or sun exposure
for MS risk across multiple racial/ethnic groups. We recruited incident MS cases and controls
(blacks 116 cases/131 controls; Hispanics 183/197; whites 247/267) from the membership of Kaiser
Permanente Southern California into the MS Sunshine Study to simultaneously examine sun exposure
and 25OHD, accounting for genetic ancestry and other factors. Higher lifetime ultraviolet radiation
exposure (a rigorous measure of sun exposure) was associated with a lower risk of MS independent
of serum 25OHD levels in blacks (adjusted OR = 0.53, 95% CI = 0.31–0.83; p = 0.007) and whites
(OR = 0.68, 95% CI = 0.48–0.94; p = 0.020) with a similar magnitude of effect that did not reach
statistical significance in Hispanics (OR = 0.66, 95% CI = 0.42–1.04; p = 0.071). Higher serum 25OHD
levels were associated with a lower risk of MS only in whites. No association was found in Hispanics
or blacks regardless of how 25OHD was modeled. Lifetime sun exposure appears to reduce the risk
of MS regardless of race/ethnicity. In contrast, serum 25OHD levels are not associated with MS risk
in blacks or Hispanics. Our findings challenge the biological plausibility of vitamin D deficiency as
causal for MS and call into question the targeting of specific serum 25OHD levels to achieve health
benefits, particularly in blacks and Hispanics.
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1. Introduction
Evidence from animal models and observational studies [1–3] in white populations shows that
higher levels of serum 25-hydroxyvitamin D (25OHD) are associated with reduced risk of multiple
sclerosis (MS). Some consider that causality has been established and vitamin D supplementation to
prevent MS is widely supported [4].
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This interpretation of the evidence is not universal. The 2011 systematic review of the Institute of
Medicine noted that “Taken together, these observational studies show widely variable outcomes for
associations between serum 25OHD levels and MS . . . lack of causal evidence further diminishes the
likelihood for a relationship between vitamin D and MS” [5].
If there is a causal biological link between vitamin D and MS, it would be expected to be present
across different racial/ethnic groups. Available studies show blacks and Hispanics have lower 25OHD
levels than whites [6] yet the incidence of MS is lower in Hispanics [7] and similar in blacks compared
to whites [7,8]. In addition, there is substantial evidence that while true 25OHD deficiency leads to
rickets in all racial/ethnic groups, ‘insufficient’ 25OHD levels in blacks do not lead to increased risk of
fractures or decline in bone mineral density [9,10].
The vitamin D-MS hypothesis originated from the observation that the prevalence of MS increases
with increasing distance from the Equator, as ultraviolet radiation (UVR) from the sun [11] becomes
less intense—but also, traditionally, where more white people live. Exposure to UVR is, in turn,
the principal natural source of vitamin D by stimulating intradermal synthesis; thus, low UVR (further
from the Equator) should lead to low vitamin D status, and a possible explanation for the geographic
distribution of MS. This relationship between UVR exposure and 25OHD levels is very strong in light
skinned individuals. However, people with darker skin tones produce less 25OHD following the same
amount of UVR exposure as whites. Furthermore, more evidence is emerging that UVR has a plethora
of immunological effects independent of the vitamin D pathway [12] that are not attenuated by darker
skin tone [13].
The only study in whites to simultaneously examine sun exposure and 25OHD showed that
25OHD levels alone do not explain the protective association between lifetime sun exposure and
MS risk [2]. Whether sun exposure or 25OHD is associated with MS risk in blacks and Hispanics is
unknown. The only previous study in non-whites found no association between serum 25OHD levels
and the risk of MS in blacks [1], but it did not measure sun exposure.
The primary purpose of the MS Sunshine study was to test the vitamin D-MS hypothesis in blacks
and Hispanics. Because the efficiency of intradermal vitamin D synthesis varies by race/ethnicity,
studying blacks, Hispanics and whites provides a natural experiment for testing the potential protective
effects of 25OHD levels on MS. This trans-ethnic population also provides a unique opportunity to test
whether higher lifetime sun exposure is potentially protective independent of adult 25OHD levels,
as the non-vitamin D immunosuppressive effects of UVR are less affected by skin color.
2. Materials and Methods
2.1. Study Population
Participants in the MS Sunshine Study were recruited from the Kaiser Permanente Southern
California (KPSC) membership between December 2011 and May 2015 via mailings and telephone
contact. KPSC is a large prepaid health maintenance organization with over 4 million members
representative of the general population in Southern California [14]. KPSC uses an integrated electronic
health record (EHR) system which includes all inpatient and outpatient encounters, diagnostic tests,
diagnoses and medications as well as some demographic and behavioral characteristics. Data were
collected from the EHR and after informed consent, structured in-person interview and blood was
drawn for 25OHD measurement (if not available in EHR) and genotyping.
2.1.1. Standard Protocol Approvals, Registrations, and Patient Consents
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the KPSC institutional review board (IRB 5962).
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2.1.2. Case Identification
Incident cases with MS or clinically isolated syndrome (CIS) were identified using similar methods
as previously described [7,15,16]. Briefly, we searched EHRs monthly for first mention of diagnostic
codes for MS or CIS and diagnoses were confirmed by an MS specialist (ALG) according to diagnostic
criteria [17–19]. Eligibility required diagnosis of MS or CIS within the past 1.5 years or symptom onset
within the past 3 years, and age ≥ 18 years (see Appendix A).
2.1.3. Control Selection
Once a case interview was completed, at least 1 control participant from the KPSC population,
matched to the case on race/ethnicity, date of birth (within 2 years), sex and home KPSC facility
(a surrogate measure for socioeconomic status) was identified from the EHR and recruited. The controls
were assigned the same index date as their matched case (symptom onset date). For participation rates
and additional details, see Appendix A.
2.2. Data Collection
Self-identified race/ethnicity was obtained from the interview. White, non-Hispanics were
classified as white; any black race regardless of ethnicity was classified as black; and those who
identified themselves as white, Hispanics were classified as Hispanics. Comparison with genetic
ancestry markers validated the accuracy of self–identified race/ethnicity.
Covariates obtained from the interview included sun exposure during weekends and holidays
(leisure time) age 6 years to date of interview, places of residence since birth, smoking (never/ever)
and vitamin D supplement use defined as ≥600 IU daily at or within 3 months prior to 25OHD
measurement. Age was defined as age at index date. Body mass index (BMI) closest to the date of
25OHD measurement was obtained from EHR.
Total serum 25OHD was measured using liquid chromatography, tandem mass spectrometry.
The sensitivity of the assay is <2.5 nmol/L. The intra-and inter-assay coefficients of variation are less
than 5.2% at 25, 62.5 and 192.5 nmol/L.
2.3. Genotyping
HLA-DRB1*15:01 status, the major risk allele for MS, was determined using a tag SNP (rs3135388).
Genetic ancestry was determined with the software STRUCTURE Version 2.3.1, University of Oxford,
Oxford, UK [20] to infer the presence of distinct populations. A genome–wide set of 67547 linkage
disequilibrium pruned loci were selected using PLINK 1.07, Center for Human Genetic Research,
the Broad Institute of Harvard & MIT, Boston, USA [21]. We compared the structure outputs from
three (Europeans, Africans, and Amerindians), five (Europeans, Africans, Amerindians, East Asians,
and Central/South Asians), and seven (Europeans, Africans, Amerindians, East Asians, Central/South
Asians, Western Asians and Oceanians) reference populations, and concluded that using 5 or 7 reference
populations did not improve upon the three-population model for estimating population admixture in
our cohort. With three populations assumed, the probability of population ancestry was estimated
by specifying a 10,000 iteration burn-in period and a 10,000 iteration follow-up of the Markov Chain
Monte Carlo model utilized by STRUCTURE.
2.4. Statistical Analysis
2.4.1. Sun Exposure
We used the most rigorous method available for assessing lifetime sun exposure. Specifically,
we calculated cumulative lifetime UVR for each participant by combining latitude of residence and
usual time outdoors obtained from a detailed residency calendar with ambient ultraviolet radiation
levels obtained from satellite-derived ground level estimates [22]. The questionnaire we used has
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been validated both for recall validity [23] and for external validity against an objective measure of
lifetime sun exposure, silicone skin casts for actinic damage in whites [24]. The average monthly UVR
estimates for each participant were summed from age 6 years to symptom onset/index date.
2.4.2. Recent Sun Exposure and 25OHD
Multivariable linear regression was used to examine the association of UVR during summer and
winter in the 12 months prior to symptom onset/index, age, sex, BMI and season of blood draw on
25OHD levels (dependent variable; log transformed).
2.4.3. Lifetime Sun Exposure, 25OHD and MS
Multivariable unconditional logistic regression was used to simultaneously estimate the
independent odds ratios (OR) and 95% confidence intervals (CI) of 25OHD and cumulative lifetime
UVR (KJ/m2) on MS/CIS by race/ethnicity. 25OHD was log-transformed (normal distribution).
Both cases’ and controls’ 25OHD values were deseasonalized by using residuals derived from
multivariable linear regression to control for the season of blood draw (April–September or
October–March) and adjusted for BMI because BMI had a strong association with 25OHD levels
but not MS/CIS risk. Models testing the association between UVR exposure, 25OHD and risk of
MS/CIS were adjusted for age, sex, genetic ancestry, smoking and HLA-DRB1*15:01 carrier status.
2.4.4. 25OHD and MS
Several additional approaches were used to try and detect an association between 25OHD
and MS/CIS in blacks or Hispanics. 25OHD was modeled as both raw and deseasonalized
values in the following ways: continuous; continuous in the log transformation; according to the
cut–points recommended by the Institute of Medicine (30, 50 nmol/L) and the US Endocrine Society
(75 nmol/L) [25]; and in quintiles. To allow for direct comparison with previous studies [1–3],
conditional logistic regression was also used to estimate the matched OR and its corresponding
95% CI for the association between MS/CIS and deseasonalized 25OHD within each racial/ethnic
category (white, black or Hispanic). For these analyses, 25OHD values were deseasonalized by fitting
a polynomial regression in controls within each race/ethnicity [2] (see Appendix A).
Sensitivity analyses excluding vitamin D supplement users were conducted for all analyses.
Two-sample t-tests were used to compare means, Wilcoxon-Mann-Whitney test for non-normally
distributed variables and χ2 or Fisher exact test to compare frequencies between two groups.
All analyses were conducted using SAS software v9.3 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Characteristics of Participants
Table 1 shows the demographic characteristics, prevalence of MS risk factors and selected factors
that influence 25OHD levels in cases and controls. There was a stronger female preponderance among
blacks than whites (p < 0.001). Hispanics were younger at symptom onset than whites or blacks
(p < 0.001). Whites were more likely to be current or former cigarette smokers (p < 0.001) and had lower
BMI (p < 0.001) than blacks and Hispanics. The median time from symptom onset to diagnosis was
slightly longer among black cases (six months; interquartile range [IQR] 1–22 months) than Hispanics
(three months, IQR 0–15) and whites (four months, IQR 1–19).
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Table 1. Selected Characteristics of Study Participants at Index Date by Race/Ethnicity.












(n = 267) p-Value
Age, mean (SD), years 38.4 (12.8) 38.5 (13.0) 0.928 32.5 (10.7) 32.6 (11.1) 0.949 39.7 (12.0) 39.9 (12.2) 0.869
Female,
n (%) 92 (79.3) 103 (78.6) 0.895 132 (72.1) 145 (73.6) 0.747 164 (66.4) 174 (65.2) 0.769
Smoking,
n (%) 27 (23.3) 33 (25.2) 0.726 44 (24.0) 38 (19.3) 0.260 115 (46.6) 90 (33.7) 0.003
BMI, mean (SD) 30.5 (7.4) 31.6 (8.1) 0.260 29.5 (6.8) 30.0 (7.0) 0.423 28.5 (6.7) 28.5 (6.9) 0.948
VitD supplement users
*, n (%) 28 (24.1) 2 (1.5) <0.001 30 (16.4) 3 (1.5) <0.001 62 (25.1) 19 (7.1) <0.001
Season **, n (%) 56 (48.3) 65 (49.6) 0.833 85 (46.5) 104 (52.8) 0.217 116 (47.0) 142 (53.2) 0.159
HLA–DRB1*15:01, n (%) 0.20 0.0002 <0.0001
GG 95 (81.9) 115 (87.8) 134 (73.2) 174 (88.3) 136 (55.1) 214 (80.1)
AG/AA 21 (18.1) 16 (12.2) 49 (26.8) 23 (11.7) 108 (44.9) 53 (19.9)
% CIS 47.4% 56.8% 59.9%
MS: multiple sclerosis; CIS: clinically isolated syndrome; SD: standard deviation; IQR: interquartile range; BMI: body
mass index; VitD: vitamin D; *: at the time of 25OHD measurement; **: season (April–September) at the time of
25OHD measurement.
3.2. Factors Associated with 25OHD Levels
UVR exposure in the 12 months prior to the index date in whites (β = 0.0025, p < 0.001) and
Hispanics (β = 0.0022, p = 0.025) but not in blacks (β = 0.0013, p = 0.24) was independently associated
with 25OHD levels. Higher BMI was strongly associated with lower 25OHD in whites (p < 0.0001),
Hispanics (p = 0.0002) and blacks (p = 0.0006). Independent effects of season on 25OHD levels were also
observed in these models (p = 0.04, <0.0001 and 0.006 in whites, Hispanics and blacks, respectively).
3.3. Cumulative Lifetime UVR, 25OHD and MS
Cumulative lifetime UVR was lower among cases compared to controls in all 3 groups (Table 2).
The protective association between higher lifetime UVR exposure and a lower risk of MS persisted
after accounting for 25OHD in blacks (p = 0.007) and whites (p = 0.020) (Figure 1) although it did not
reach statistical significance in Hispanics (p = 0.071).
Serum 25OHD levels were higher among whites than blacks, and Hispanics had intermediate
values (Table 2). Serum 25OHD levels were significantly lower among white cases than controls
but there was no significant difference in 25OHD levels between black or Hispanic cases and their
respective controls (Table 2). The median time from diagnosis to 25OHD measurement was somewhat
shorter among black cases (1 month, IQR-1–9), than Hispanics (4 months, IQR 0–12) and whites
(4 months, IQR 0–10).
Table 2. Individual Relationships between Cumulative Ultraviolet Radiation Exposure or Serum
25-hydroxyvitamin D and Multiple Sclerosis.
Cumulative UVR Dose *, 1000 KJ/m2 Serum 25-Hydroxyvitamin D, nmol/L
n Mean (SD) Adjusted OR (95% CI) ** p-Value Median (IQR) Adjusted OR (95% CI) *** p-Value
Blacks
cases 116 1.43 (0.77) 0.53 (0.32–0.85) 0.009 43.7 (32.4, 74.9) 1.21 (0.73–2.02) 0.455
controls 131 1.63 (0.79) 47.4 (30.0, 64.9)
Hispanic
cases 183 1.14 (0.61) 0.65 (0.41–1.01) 0.057 54.9 (42.4, 69.9) 0.74 (0.45–1.29) 0.290
controls 197 1.22 (0.68) 57.4 (44.9, 69.9)
Whites
cases 247 1.53 (0.79) 0.67 (0.48–0.93) 0.017 67.4 (49.9, 87.4) 0.52 (0.31–0.87) 0.010
controls 267 1.64 (0.83) 72.4 (59.9, 92.4)
SD: standard deviation; IQR: interquartile range; UVR: ultraviolet radiation; OR: Odds Ratio; CI: confidence
intervals; * from age 6 years to index date; ** adjusted for age, sex, smoking, genetic ancestry and HLA–DRB1*15:01;
*** deaseasonalized log(25OHD) accounting for body mass index and adjusted for age, sex, smoking, genetic
ancestry and HLA-DRB1*15:01.
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lifetime ultraviolet radiation exposure (Panel B). Serum 25-hydroxyvitamin D levels were log 
transformed, adjusted for BMI and deseasonalized. 
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lower odds ratio of MS/CIS was found only in whites (p = 0.013; Figure 1; Tables 2 and 3). In blacks, 
25OHD levels > 75.0 nmol/L were associated with increased risk of MS although this did not reach 
statistical significance (Table 3). Use of vitamin D supplements at the time of 25OHD measurement 
was more common among cases than controls and more common among whites and blacks 
compared with Hispanics (Table 1). Excluding supplement users did not significantly alter the results 
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adjusted for age, smoking and BMI. 
4. Discussion 
Our findings demonstrate that there is a strong and consistent association between higher 
lifetime sun exposure and MS risk across racial/ethnic groups. However, the protective association 
Figure 1. Si lt e fects of lifetime ultraviolet radiation exposure and 25-hydroxyvitamin
D on MS risk. D pict d are the mutually adjusted odds ratios (OR) and 95% confidence intervals
(95% CI) of the i pendent associations of lifetime ultraviole radiati n exposure (Panel A) or serum
25- roxyvita in D levels (Panel B) with risk of multiple sclerosis/clinically isolated syndrome within
each racial/ethnic group obtained from the same model. Od s ratios depicted are adjusted by age, sex,
smoking, genetic ancestry, HLA–DRB1*15:01(rs3135388) 25-hydroxyvitamin D (Panel A) or lifetime
ultraviolet radiation exposure (Panel B). Serum 25-hydroxyvitamin D levels were log transformed,
adjusted for BMI and deseasonalized.
3.4. 25OHD and MS
Regardless of how 25OHD was defined, models either adjusted or unadjusted, raw,
deseasonalized and matched deseasonalized, an association between high 25OHD and a significantly
lower odds ratio of MS/CIS was found only in whites (p = 0.013; Figure 1; Tables 2 and 3). In blacks,
25OHD levels > 75.0 nmol/L were associated with increased risk of MS although this did not reach
statistical significance (Table 3). Use of vitamin D supplements at the time of 25OHD measurement
was ore common among cases than controls and more common among whites and blacks compared
with Hispanics (Table 1). Excluding supplement users did not significantly alter the results (data
not shown).
Table 3. Matched pairs a alysis: Odds Ratios of Multiple Sclerosis by Threshold Values of Serum
25–Hydroxyvitamin D among Blacks, Hispanics and Whites.
25OHD Blacks Hispanics Whites
nmol/L Cases n Controls n OR (95% CI) Casesn Controln OR (95% CI) Casesn Controlsn OR (95% CI)
<50.0 60 65 ref 69 62 ref 61 26 ref
50.0–75.0 20 36 0.54 (0.26–1.10) 65 76 0.76 (0.47–1.26) 91 104 0.30 (0.16–0.55)
>75.0 29 15 2.03 (0.92–4.47) 31 34 0.75 (0.40–1.41) 85 111 0.27 (0.15–0.50)
Presented adjusted odds ratios (OR) and 95% confidence intervals (95% CI) of the association between pre-specified
25OHD threshold values and MS/CIS among blacks, Hispanics and Whites. The 25-hydroxyvitamin D values of
cases are deseasonalized based on the matched control values. OR are adjusted for age, smoking and BMI.
4. Discussion
Our findi gs demonstrate that there is a strong and consistent association between higher lifetime
sun exposure and MS risk across racial/ethnic groups. However, the protective association of sun
exposure is not explained by current serum 25OHD levels in blacks, Hispanics or even fully in
whites. This indicates that the protective effect of sun exposure is most likely mediated through
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immunomodulatory mechanisms independent of vitamin D. Taken together with previous data from
multi-ethnic studies of determinants of vitamin D status [6,26,27], these findings call into question the
common practice of targeting a specific serum 25OHD level with the expectation of health benefits,
particularly in blacks and Hispanics.
We looked very carefully for any evidence of an association between 25OHD and MS in non-white
populations, in view of the purported causal association between vitamin D deficiency and increased
risk of MS [4]. We found evidence to support an association between higher 25OHD level and reduced
MS/CIS risk among whites, but no evidence of any protective effect in Hispanics and blacks. Potential
bias introduced by case-control design should be in the direction of finding such an association (as we
and others found in whites), as MS patients, particularly those with disability, often avoid sun exposure
because heat makes them feel worse. Likewise, multiple statistical tests would be expected to lead to
false positive results rather than consistently negative findings.
If there is a causal biological link between vitamin D and MS, it would be expected to be present
across different racial/ethnic groups. Randomized controlled trials to prove such causality for the
onset of MS are not feasible; this requires innovative approaches to rigorously test the hypothesis.
Mendelian randomization has been used in an attempt to establish causality between vitamin D
and MS in whites [28,29] but it is unclear if the key assumptions required for this approach to be
valid have been met. We believe that our findings, from a rigorously conducted observational study,
with detailed measurement of both sun exposure and 25OHD levels (available in very few studies),
and across different races (available only in this study) provides the strongest test to date of the vitamin
D-MS hypothesis.
These findings are important because many experts are recommending vitamin D supplementation
to prevent MS. In addition, the apparent association between low 25OHD and MS in whites has led to an
explosion of vitamin D-MS studies while neglecting rigorous investigations of alternative hypotheses.
Our findings suggest that while 25OHD may be an excellent surrogate measure of sun exposure
in whites and certainly easier to measure, focusing on risk factors common to multiple racial/ethnic
groups is more likely to lead to scientific advances.
While our finding that higher 25OHD is associated with a lower risk of MS in whites appears
consistent with the 3 previous studies that have examined this question in adults [1–3], there are
important discrepancies. A threshold effect was found in 2 studies but at different values (~100 [1]
or ≥75 nmol/L [3]), a linear association in 1 study without a threshold effect [2]; and trends across
quintiles in 2 studies [1,2]. We found a linear relationship only in log transformation (consistent with
much larger population studies), and a positive association with MS in whites at all pre-determined
threshold values and across quintiles. This is despite strikingly similar distributions of serum 25OHD
levels in whites across these studies [1–3] and ours.
Although it is possible that the differences that we see between racial/ethnic groups are due to
some unknown genetic pathways, we favour a less complex explanation that the association between
serum 25OHD and MS is found only in whites because it is a good surrogate measure of sun exposure
in whites but not darker skinned individuals. Sun exposure is a major source of vitamin D synthesis by
skin. Yet, the same amount of UVR exposure results in a smaller increase in 25OHD in dark-skinned
compared to light-skinned groups [5]. Thus, it is possible that sun exposure is protective for MS but
that serum 25OHD levels do not quantitatively capture this exposure in darker skinned individuals.
Our data are consistent with previous studies that examined environmental influences on serum
25OHD levels in blacks, Hispanics and whites [6,27,30,31]. We found a similarly strong correlation
between recent UVR exposure and 25OHD levels in whites and Hispanics but less so in blacks [5]; and
the expected effect of obesity and season on 25OHD levels in all 3 groups [6].
Our findings in whites are similar to those reported by the AusImmune Study [2] and a Swedish
study [32], which both showed that the protective association of sun exposure is independent of the
association between serum 25OHD and MS/CIS.
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That sun exposure could decrease the risk of MS through non–vitamin D dependent pathways is
biologically plausible. UVR exposure results in immunomodulation through multiple mechanisms
including generation of T regulatory cells, B suppressor (regulatory) cells and production of
immunosuppressive lipid mediators and alarmins [33]. UVR has also been shown to suppress the
animal model of MS (experimental autoimmune encephalomyelitis) through pathways independent of
vitamin D [34–36].
An alternative explanation for our findings is that total serum 25OHD may not be a good reflection
of the amount of bioavailable vitamin D—the form that is important in regulating the immune system.
There is some evidence to support this in blacks who express a different dominant isoform of the
vitamin D transporter protein (vitamin D-binding protein, DBP) than whites and Hispanics. The DBP
found in most blacks is the most efficient transporter of 25OHD and its metabolites to target tissues [37]
and is associated with higher bioavailable 25OHD levels. This may explain why, despite quite low
total 25OHD levels, most blacks are not physiologically vitamin D deficient [38]. But this difference in
bioavailable 25OHD levels would not explain why we did not find an association between 25OHD
and MS in Hispanics whose DBP isoforms are like whites. This hypothesis is addressed in subsequent
analyses from the MS Sunshine study [39].
Limitations of this study include the case-control design necessitating that most 25OHD measures
were obtained after symptom onset (although very close to the time of diagnosis) and sun exposure
was obtained retrospectively. MS often results in sun avoidant behavior due to heat sensitivity [40]
which can cause an exaggerated association between low 25OHD and MS particularly in prevalent
cases. This most likely explains the observed lower 25OHD levels in a previous study of prevalent
black MS cases compared to controls [41] and may explain the strong association we found in whites,
but does not explain the lack of association we found in Hispanics and blacks. Interestingly, 25OHD
levels do not differ between prevalent Hispanic MS cases or controls [42], or decline with increasing
disability as has been shown in whites [43]. Another limitation is that we relied on a single measure of
25OHD from adulthood. While a single measure is a reliable indicator of long term vitamin D status in
adults [44] we cannot make any inference about the correlation with childhood/adolescent vitamin D
status, which may be a critical risk period for the development of MS.
Similarly, recall bias of sun exposure would be expected to bias the results toward the null and
does not explain the consistent protective association of UVR with MS seen across racial/ethnic groups.
In addition to sun exposure, cumulative UVR, the most rigorous method available for estimating
lifetime sun exposure, relies on places of residence and ambient UVR from geographic information
services both of which are not subject to recall bias.
During the course of this study, vitamin D supplement use after diagnosis also became popular
but sensitivity analyses removing these participants did not significantly alter the findings. Selection
bias, particularly among controls is another potential concern but comparison of age, smoking and
BMI of participating and declined participants did not reveal significant differences. Women were
more likely to participate regardless of case/control status. We also cannot exclude the possibility that
the association between sun exposure and MS is a chance finding as a replication cohort of incident
blacks or Hispanics with sun exposure and 25OHD measurements does not yet exist. However,
the consistency between findings in blacks and Hispanics and with whites from the AusImmune
Study [2] and Swedish study [32] is reassuring. Replication of our key findings should be addressed in
future studies.
This study highlights how multi–ethnic studies can lead to novel insights into disease. While we
have been able to demonstrate a clear and consistent association with EBV [15] and sun exposure on
MS risk across all 3 racial/ethnic groups, we are unable to find a similarly consistent association with
cytomegalovirus infection [15] or serum 25OHD levels which strongly implies non–causal associations.
Low serum 25OHD levels have been associated with multiple conditions and supplementing people
with low 25OHD levels in the hopes of health benefits is popular. But results of randomized controlled
trials have not demonstrated convincing health benefits of vitamin D supplementation [45,46].
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Our findings suggest that time in the sun may be more beneficial than vitamin D supplementation for
reducing the risk of MS, particularly in blacks and Hispanics.
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Appendix A
A.1. Supplementary Methods
A.1.1. Study Population, Case and Control Identification and Recruitment
KPSC provides comprehensive health care to ~20% of the population in the geographic area
it serves [14]. To identify potentially eligible cases, we searched the complete electronic health
record (EHR) electronically monthly for first mention of ICD-9 diagnostic codes for MS or CIS
1 January 2011–31 December of 2014. Diagnoses were confirmed by an MS specialist (ALG) after
complete EHR review according to revised McDonald criteria for MS [17] and consensus definitions
for idiopathic transverse myelitis (TM) [18,19]. All diagnoses of optic neuritis (ON) were confirmed by
ophthalmologists. Symptom onset date and date of diagnosis were validated by structured interview.
Patients who met diagnostic criteria for neuromyelitis optica spectrum disorder [43] were excluded.
Due to resource limitations and because the primary goal was to study non–white populations,
recruitment of white cases was stopped after the target of n = 250 had been reached. Study participants
of Asian/Pacific Islander (56 participants) and Multiple (2 participants) races were excluded from the
analyses due to small sample size. We plan on examining Asian/Pacific Islanders separately once we
have recruited sufficient number of participants as we expect the effects of vitamin D and sun exposure
on the risk of MS to differ from blacks and whites.
There are slightly more controls in the MS Sunshine Study than cases primarily because sometimes
the race/ethnicity indicated in the EHR did not match the participant’s self-reported race/ethnicity.
This mis-match between the EHR and self-reported race/ethnicity occurred primarily with white,
Hispanics and white, non-Hispanics. To identify eligible controls matched to cases on race/ethnicity,
race/ethnicity was initially pulled electronically from the EHR. If, during the structured in-person
interview, the control reported a different race/ethnicity than their respective case, another control
was recruited for the case until a true racial/ethnic match was completed. Asians (total cases and
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controls n = 57) and people of multiple races (n = 2) were recruited but not included in the analyses
due to small sample.
The number and proportion of study participants that had 25OHD levels available in their
complete electronic health record from prior to symptom onset/index date are as follows: blacks,
17 (14.7%) of cases and 14 (10.7%) of controls; Hispanics, 17 (9.3%) cases, 17 (8.6%) controls; and whites,
20 (8.1%) cases, and 21 (7.9%) of controls.
A.1.2. Genotyping
The genotyping data was available on 1159 (97.6%) of the 1187 black, Hispanic or white
participants who had completed the study protocol by 6/2/2015. Eighteen participants were excluded
due to missing phenotype data as follows: 5 due to missing serum 25(OH)D values; 11 for missing
cumulative UVR data; and 2 for missing smoking status. The final analysis cohort included 1141(96.1%)
participants: 247 Blacks (116 cases/131 controls), 380 Hispanics (183 cases/197 controls) and 514 whites
(247 cases/267 controls).
These participants were genotyped successfully for 697,895 SNPs using Illumina’s
HumanOmniExpressExome v1.2. DNA Analysis BeadChips were produced by the Vincent J. Coates
Genomics Sequencing Laboratory (GSL) at the University of California, Berkeley. DNA samples were
quantitated using the Nanodrop ND–1000 and subsequently normalized and plated for processing.
The samples were processed using the Illumina Infinium HD Assay Super protocol. DNA samples were
denatured, neutralized, and prepared for amplification. The amplified product was then fragmented,
precipitated, and collected by centrifugation. The precipitated DNA was resuspended in hybridization
buffer and subsequently hybridized to a beadchip. The beadchip was then prepared for extension
and staining. Once the assay was completed, the chips were dried and placed on the scanner for data
collection. Data was then QC’d using Genome Studio and Plink.
From Within GenomeStudio, various QC measures were checked including call rates, sex
discrepancies, reproducibility and heritability of replicates and CEPH control trios, as well as
performance of internal Illumina controls. Any samples with the above discrepancies were noted down.
Samples with call rates of less than 90% or less than 99% were also noted. In addition, the following
data from PLINK1.07 [21] were filtered: N/percent of SNPs with call-rate < 90%, N/percent of SNPs
with Hardy Weinberg (all samples) p-value < 0.000001, N/percent of SNPs with MAF < 0.01.
A summary of Control target intensities was then created to evaluate the performance of Illumina’s
internal controls. Illumina includes several control targets for the purpose of QC at various stages.
The Staining, Extension, Target Removal, and Hybridization controls are all sample-independent
measures that show the performance of the assay. The Stringency, Non-Specific Binding and
Non–Polymorphic controls are all sample-dependent controls.
We performed sex check and tested the deviation from Hardy-Weinberg equilibrium within
racial/ethnic group on SNPs using PLINK 1.07.
A.1.3. Deseasonalized 25OHD Values for Other Analyses
For analyses that include unmatched cases and controls, 25OHD levels were deseasonalized for
both cases and controls and did not result in significantly different findings. Seasons were combined
into 2 seasons, winter (October–March) and summer (April–September) based on the inflection points
of the best-fit polynomial regression (quadratic function) of the monthly variation of 25OHD values
among controls. This is consistent with Southern California’s annual fluctuation in temperatures and
daylight hours. We did not detect significant variation between fall and winter or spring and summer.
A.1.4. Cumulative Lifetime UVR
Cumulative lifetime UVR for each participant was calculated using previously validated
methods [2]. Average monthly estimates derived by linking latitude and longitude of residence
with satellite-derived ground level estimates of ambient UVR multiplied by proportion of time in the
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sun during summer were summed from age 6 years to symptom onset/index date. Specifically, we
used the proportion of self-reported hours outside in the sun for weekends (26 days) and holidays
(14 days) in the season (summer: (sun time in hour/12) × 40 to calculate the personal cumulative
leisure-time UVR dose in summer for each participant. The leisure-time UVR dose was calculated as
ambient UV x proportion of day in the sun, then summed over the relevant period, from 6 years of age
until symptom onset/index date.
A.1.5. UVR 12 Months Prior to Symptom Onset/Index Date and 25OHD
Multivariable linear regression was used to examine the association of UVR during summer and
winter 12 months prior to symptom onset/index and log–transformed 25OHD levels including age at
index date with sex, BMI and smoking as covariates. We used the proportion of self-reported hours
outside in the sun for weekends (26 days) and holidays (14 days) in the season (summer: (sun time in
hour/12) × 40 and winter (sun time in hour /8) × 40) to calculate the personal leisure-time UVR dose
in summer and winter 12 months prior to symptom onset/index date for each participant.
A.1.6. Deseasonalized 25OHD Values for Matched Pairs Analyses
The circulating 25(OH)D level varies over the year; it tends to be higher in summer than in
winter, due to the difference in sun exposure habits and ultraviolet intensity. The vitamin D level for
case and matched control could be measured at different specific time point. Thus, is important to
adjust for the seasonal fluctuation in the measurement of the vitamin D levels. Serum 25OHD values
were deseasonalized by fitting a polynomial regression in controls within each race/ethnicity [20].
A quadratic function provided the best fit of the values across weeks within a calendar year.
The controls’ 25OHD levels were adjusted by using the fitted curve to the 25OHD levels at the
blood collection date of the matched cases and adding individual residual from the model fit (adjusted
vitamin D = predicted vitamin D + residual). The cases’ 25OHD levels were unchanged to allow for
direct comparison with previous studies [2]. The formulas are as follows:
1. Blacks: y = 16.68 + 0.51 × x − 0.03 × x2 + yresid
2. Hispanics: y = 19.75 + 0.06 × x − 0.02 × x2 + yresid
3. Whites: y = 24.11 + 0.29 × x − 0.08 × x2 + yresid
y: the seasonal adjusted 25OHD level
x: 1st blood collect date in week
yresid: residual 25(OH)D level
A.1.7. Matched Pairs Analyses
To allow for direct comparison with previous studies, conditional logistic regression was used to
estimate the OR and 95% CI according to the IOM 25OHD thresholds. Due to the small number of
participants with severe vitamin D deficiency (≤30 nmol/L) this was combined with the ≤50 nmol/L
group. The conditional logistic regression analysis resulted in eliminating a total of 113 unmatched
participants (25 blacks, 44 Hispanics and 44 whites).
A.2. Supplementary Results
To assess for participation bias smoking status was identified from the electronic health record and
age was defined as age upon becoming eligible for recruitment for study participants and those who
declined participation. All participants as of 31 December 2015 are included in this table (Table A1)
including those recruited after the cut–off inclusion for the analyses in the manuscript of 2 June 2015
as well as those with some missingness precluding inclusion in analyses.
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Table A1. Participation rates and comparison of participating and declined participants.











Blacks n = 126 n = 40 n = 142 n = 143
age, mean (SD)
years 40.7 (12.7) 42.6 (13.1) 0.41 41.0 (12.8) 42.8 (12.7) 0.22 0.91
female, n (%) 99 (78.6) 25 (62.5) 0.04 109 (76.8) 108 (75.5) 0.81 0.10
obesity, n (%) 54 (42.9) 18 (45.0) 0.81 65 (45.8) 68 (48.9) 0.60 0.66
BMI, mean SD) 29.8 (7.2) 30.4 (6.8) 0.68 30.8 (7.7) 31.1 (7.9) 0.75 0.57
participationrate 75.9% 49.8%
Hispanics n = 192 n = 79 n = 207 n = 219
age, mean(SD)
years 34.5 (10.8) 37.5 (14.3) 0.10 34.2 (10.9) 37.4 (13.2) 0.01 0.96
female, n (%) 138 (71.9) 50 (63.3) 0.16 152 (73.4) 141 (64.4) 0.04 0.86
obesity, n (%) 79 (41.2) 24 (30.8) 0.11 84 (41.0) 72 (33.0) 0.09 0.72
BMI, mean (SD) 29.6 (6.6) 29.1 (7.3) 0.58 29.8 (7.1) 28.3 (5.9) 0.02 0.43
participation rate 70.9% 48.6%
Whites n = 252 n = 86 n = 274 n = 315
age, mean(SD)
years 42.5 (12.3) 41.9 (13.5) 0.71 42.3 (12.4) 46.3 (12.0) <0.01 <0.01
female, n (%) 168 (66.7) 56 (65.1) 0.79 179 (65.) 181 (57.5) 0.05 0.20
obesity, n (%) 79 (31.4) 33 (38.4) 0.23 89 (32.7) 96 (30.6) 0.58 0.17
BMI, mean (SD) 28.5 (6.8) 28.5 (6.7) 0.98 28.6 (6.9) 28.1 (6.5) 0.37 0.54
participation rate 74.6% 46.5%
*: at or closest to the time of eligibility for the study; SD: standard deviation.
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